Wedbush initiated coverage on Mirati Therapeutics (NASDAQ: MRTX) with an Outperform rating and a price target of $29.00.Analyst Heather Behanna ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE